CHALLENGE THE STATUS QUO
Signed in as:
filler@godaddy.com
OFFER A SOLUTION TO INACCURACY
EARLY DETECTION IS CRUICIAL
Prostate cancer will affect 1 in 7 men. 1 The standards for screening and biopsy blindly sample the prostate without knowing where the cancer is, if any. We’re here to set a new standard of care with MRI-targeted fusion biopsies.
1 Statistics – Prostate Cancer Canada. (n.d.). Retrieved from prostatecancer.ca
Meet the Fusion Bx - A few guiding principles
Accuracy - Reliably targets lesions using MRI-ultrasound fusion
Compared to ultrasound imaging, MRI can be considered the “Gold Standard” for detecting lesions. MRI-targeted biopsies with Fusion Bx addresses potential sources of inaccuracy during biopsy procedures by targeting 3 key areas: prostate deformation, patient motion and registration.
Efficiency - Simplified workflow minimizes training and procedural times
Innovative technology doesn’t need to be complicated. Driven by end users, our 4-step guided workflow and semi-robotic arm eases the procedure for both physicians and patients.
Accessibility - Cost effective and easy to use fusion biopsy solution
Through rigorous testing and a fine attention to detail, we’ve developed a quality cost effective solution for fusion biopsies. Thoughtful engineering, multi-probe compatibility and accommodating customer service makes our system accurate, efficient and accessible to everyone.
Get accurate and meaningful results faster with a targeted approach.
Fusion Bx can yield cancer detection rates of 93% or greater for PI-RADS 4 and 5 lesions compared to only 20% with systemic biopsies.
